Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation.What does Mobotinib pay attenti···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：255
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation. Exkivity reduces the growth of···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：247
Capmatinib targets the activity of MET receptors and blocks the tumor cell growth signaling pathway driven by MET receptors, enabling effective treatment for patients with non-smal···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：316
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-competitive properties, which can significantly inhibit the proliferation and migration ability of c-Met···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：300
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosine kinase, making it particularly suitable for lung cancer patients with MET14 exon skipping mutation···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：311
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and blocking the proliferation and migration of tumor cells. Exkivityhas been approved by the United States ···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：250
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor activity, especially for the treatment of c-Met-dependent tumors.What are the side effects that can occ···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：288
Exkivity effectively inhibits the growth and spread of tumor cells by precisely targeting EGFR exon 20 insertion mutations, providing a new treatment option and hope for patients w···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：281
Capmatinib is a MET inhibitor developed by Novartis specifically for patients with non-small cell lung cancer with specific gene mutations.What are the possible side effects when u···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：241
Exkivityis an innovative third-representative dermal growth factor receptor (EGFR) tyrosine kinase inhibitor specifically designed for the treatment of patients with non-small cell···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：233
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, primarily for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutatio···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：254
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) in patients with mutations in the MET gene, particularly MET exon 14 skipping mutations.Wha···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：264
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1642025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
